BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced safety and tolerability data at one year from four Duchenne muscular

Trawick International (TI) today announces new strategic partnerships with Crum & Forster SPC and On Call International to further optimize the customer experience.

Immunovia AB (publ) (“Immunovia”) today announced the company will host a Virtual Investor Day on Tuesday, June 30, 2020 , from 2:00 to 4:00 pm CET . The online event will feature presentations by Immunovia’s Chairman, Carl Borrebaeck ; CEO, Mats Grahn ; Chief Commercial Officer, Laura Chirica ; Senior VP Sales North America,

Steele, former president/chief executive officer of Geisinger Health System, will lead the center’s board of directors

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have entered a two-year strategic partnership with Xencor, Inc.

Biolinq Inc., the San Diego-based medical device company, announced today that the company has successfully demonstrated the feasibility of a minimally invasive continuous glucose monitor (CGM), showing a high correlation between dermal interstitial glucose and venous blood glucose.

Today, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible.

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the closing of its previously announced public offering of 3,906,250 shares of its common stock at a public offering price of $32.00 per share.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in fireside chats at two upcoming virtual investor conferences.

Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the first quarter of fiscal 2021, the period ending April 30, 2020. All figures are reported in U.S. dollars. Q1 ending April 30, 2020 Q1 ending April 30, 2019 Sales 839,322 1,221,484 Net Income 58,339 196,786 Income per common share - basic 0.02 0.06